-
Ocaliva FDA Adverse Events Reports for Hepatobiliary System Cases: An Analysis as of October 2020
Lack of Warnings in Current Ocaliva Drug Label for Some Serious Side Effects Involving Liver, Gallbladder, Bile Ducts (Posted by Tom Lamb at DrugInjuryWatch.com) We are still wondering how the current FDA…
-
Potential Ocaliva – Liver Disorder Safety Signal Being Investigated by FDA as Side Effects Risk
October 2020 News Report Reveals "New" Ocaliva Liver Safety Issue, Which Had Been Under the Radar Previously (Posted by Tom Lamb at DrugInjuryWatch.com) Ocaliva (obeticholic acid) was approved by the FDA in…
-
Beovu: Should Use of This Eye Drug be Suspended Until Safety Investigation is Finished?
Numerous Case Reports of Occlusive Retinal Vasculitis and Vision Loss in Patients Following Beovu Injections (Posted by Tom Lamb at DrugInjuryWatch.com) As early as May 2020 it was suggested by the authors…
-
Safety of Beovu: A Lingering Issue Which Novartis Attempts to Counter with Recent Study Results
Recent Beovu Label Change in Europe Adds Information About Retinal Vasculitis and Retinal Vascular Occlusion (Posted by Tom Lamb at DrugInjuryWatch.com) In mid-September 2020 Novartis announced the results of a Phase 3…
-
Report on FDA Belviq Recall Decision Provides New Information About Excess Cancers Risks
Belviq Safety Data Review Found Higher Rates of Colorectal Cancer, Pancreatic Cancer, and Lung Cancer (Posted by Tom Lamb at DrugInjuryWatch.com) The FDA's decision to request that the pharmaceutical company Eisai recall…
